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The management of Hodgkin’s lymphoma (HL) recurring after allogeneic stem cell transplantation is chal-
lenging. We retrospectively describe 18 adults treated with bendamustine followed by escalated donor
lymphocyte infusion. Hematological toxicity was manageable (39% grade III to IV neutropenia and 28% grade
III to IV thrombocytopenia). The overall response rate was 55%, with 3 complete and 7 partial responses.
Median overall and progression-free survival were 11 (range, 1 to 52) and 6 (range, 1 to 28) months,
respectively. One-year overall survival of responders (complete or partial) was 70% (95% conﬁdence interval,
42% to 98%), although it was only 16% for nonresponders (n ¼ 8). Our data show that bendamustine followed
by donor lymphocyte infusion is feasible and can be efﬁcacious as salvage treatment in HL relapsing after an
allograft.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is a con-
ventional approach for patients with Hodgkin’s lymphoma
(HL) relapsing or refractory (rel/ref) to autologous hemato-
poietic stem cell transplantation [1-6]. However, the prog-
nosis of advanced HL for patients undergoing allo-SCT
remains poor, with an expected progression-free survival
(PFS) ranging from 18% to 39%.
Management of patients relapsing after allo-SCT is not
standardized and different approaches, such as reduction of
immunosuppression, donor lymphocyte infusion (DLI), a
second allogeneic SCT, and new drugs, including brentux-
imab vedotin, have been reported.
Bendamustine is an active agent in rel/ref HL patients,
with a overall response rate (ORR) of 50% to 78% [7-10]. DLI in
patients relapsing after allo-SCT induces a response rate
(complete plus partial) in the 30% to 50% range and a median
duration of 7.5 months [2,11]. Accordingly, we combined
bendamustine and DLI in HL patients rel/ref after allo-SCT to
synergistically provide reduction of tumor burden by
chemotherapy followed by the antilymphoma activity of DLI.
So far, this therapeutic option has been reported only in 2
patients [12]. We describe a cohort of 18 HL patients treated
with bendamustine and DLI for HL rel/ref after allo-SCT.
PATIENTS AND METHODS
Over an 8-year period (2006 to 2013), we report on 18 adult patients
with HL who experienced disease progression (PD) after a reduced-
intensity conditioning followed by an unmanipulated allo-SCT and wereedgments on page 1447.
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14.05.024considered eligible for salvage treatment with bendamustine followed by
DLI (Table 1). Patients were treated after inclusion into a compassionate-use
program and the provision of written informed consent. The median
follow-up from relapse after allo-SCT was 310 days (range, 60 to 2939 days).
Donor type was matched related sibling (n ¼ 4), matched unrelated donor
(MUD) (n ¼ 2), and mismatched related donor (MMRD) (haploidentical
donors n ¼ 9; 7/10 HLA-match, n ¼ 1; 8/10 HLA-match, n ¼ 1; 9/10 HLA-
match n ¼ 1). Patients were treated in 2 centers in Milan, Italy: San Raf-
faele Hospital (patient no. 1 to 8) and Humanitas Cancer Center (patient no.
9 to 18). Patients were considered eligible for bendamustine when they had
(1) performance status (Eastern Cooperative Oncology Group)  2; (2) no
immunosoppression ongoing; and (3) no active infection. Patients were
considered eligible for DLI after bendamustine in case of (1) absence of
active graft-versus-host disease (GVHD), (2) no previous grade III to IV acute
GVHD or severe chronic GVHD, and (3) no progression during bendamus-
tine treatment. Bendamustine was administered at the dose of 120 mg/m2
on days 1 and 2 of 28 days cycles. Eight patients treated at San Raffaele
hospital received also rituximab (375 mg/m2 on day 2 of each cycle) in
combinationwith bendamustine [12-14]. Adequate hematopoietic recovery
was required before each cycle (absolute neutrophil count 1000/mL;
platelet count 75,000/mL) and treatment was delayed or eventually the
dose was reduced if these criteria were not met.
Donor lymphocytes were collected by apheresis according to standard
center protocol and the desired amount of CD3þ donor T lymphocytes was
infused after cytoﬂuorimetric counting without any further manipulation.
The initial dose of donor lymphocytes was .5  107 CD3þ T cells/kg of re-
cipient’s body weight (Humanitas Cancer Center) or 1  107 T cells/kg (San
Raffaele Hospital), for patients who received a graft from a sibling donor and
.5  106 CD3þ T cells/kg (Humanitas Cancer Center) or 1 106 CD3þ T cells/
kg (San Raffaele Hospital) in case of MUD or MMRD. DLI was given 5 to
10 days after each of 2 courses of bendamustine at one-half logarithmic dose
escalation. After disease restaging, in the absence of complete remission
(CR), limiting toxicities, grade III to IV acute GVHD or severe chronic GVHD,
patients were treated with a second course of 2 cycles of bendamustine
followed by one-half logarithmic dose escalated DLI up to 5  107 CD3þ
T cells/kg from a sibling donor or 5  106 CD3þ T cells/kg from a MUD or
MMRD. Kaplan-Meier estimates of overall survival (OS) were provided for all
patients, starting from the ﬁrst bendamustine cycle. Hazard ratio of mor-
tality was calculated with Cox regression using response as a time-
dependent variable.RESULTS
Median age was 33 years (range, 21 to 48). Ann Arbor-
Cotswold stage at relapse was III to IV in 16 of 18 patients.
Table 1
Patient’s Characteristics
Patient
No.
Sex/Age, yr Hystotype,
Stage
Disease
Status at
Allo-SCT
Donor Type,
HLA Match
Conditioning
Regimen
GVHD
Prophylaxis
Time, SCT
to Benda, d
No. of
Cycles
No. of
DLI
T Cell
Dose/kg
aGVHD
after DLI
cGVHD
after DLI
Best Response
after Benda [15]
Outcome and time
from First Benda to
Last Follow-up
# 1 M/41 MC-IV PR MUD 10/10 Treo-Flu-ATG Rapa/MMF 330 1 0 PD Dead (PD), 14 d
# 2 M/38 NS-IV SD MMRD 5/10 Treo-Flu-ATG Rapa/MMF 525 6 1 1  106 IV None CR Alive (PD), 19 mo
# 3 M/37 NS-IV CR MMRD 5/10 Treo-Flu-ATG Rapa/MMF 453 2 0 PD Dead (PD), 3 mo
# 4 M/44 NS-III PR MMRD 5/10 Treo-Flu-ATG Rapa/MMF 225 4 0 SD Dead (PD), 4 mo
# 5 F/44 Classic-IV PR MMRD 8/10 Treo-Flu-ATG Rapa/MMF 272 5 2 1  106 (I)
5  106 (II)
0 Moderate (I)
severe (II)
CR Alive (PR), 40 mo
# 6 F/42 NS-IV SD MMRD 5/10 Treo-Flu-ATG Rapa/MMF 334 6 1 1  106 0 Moderate PR Dead (infection),
12 mo
# 7 M/28 NS-III PR MMRD 9/10 Treo-Flu-
ATG -TBI
Rapa/MMF 279 4 0 PR Alive (CR after
brentuximab) 14 mo
# 8 F/46 NS-III CR MMRD 5/10 Treo-Flu-ATG Rapa/MMF 664 4 2 1  106 (I)
5  106 (II)
0 (I)
IV (II)
None (I)
NE (II)
CR Dead (GVHD), 7 mo
# 9 M/29 NS-II CR MUD 10/10 Treo-Flu-
ATG-TBI
Rapa/MMF 586 4 1 1  106 0 moderate PR Alive (PR), 12 mo
# 10 M/33 NS-IV PR MRD 10/10 Thio-Flu-CTX CsA/MTX 120 1 1 .5  107 0 none PD Dead (PD), 30 mo
# 11 M/36 NS-IV PR MRD 10/10 Thio-Mel-
CTX
CsA/MTX 995 7 0 PR Alive (CR after
brentuximab) 45 mo
# 12 M/18 Classic-IV SD MRD 10/10 Flu-CTX CsA 1456 9 3 .5  107 (I)
.5  107 (II)
1  107 (III)
0 none PR Alive (CR after II
allo-SCT) 53 mo
# 13 M/25 NS-IV PR MMRD 7/10 Flu-CTX-TBI CTX/FK506/
MMF
189 1 0 PD Dead (PD), 5 mo
# 14 M/43 NS-IV CR MRD 10/10 Thio-Flu-CTX CsA/MTX 399 7 3 .5  107 (I)
1  107 (II)
5  107 (III)
0 none PR Alive (PD), 20 mo
# 15 M/24 NS-IV CR MMRD 5/10 Flu-CTX-TBI CTX/FK506/
MMF
613 2 0 PD Alive (PD), 4 mo
# 16 F/34 MC-IV CR MMRD 5/10 Flu-CTX-TBI CTX/FK506/
MMF
133 6 2 .5  106 (I)
1  106 (II)
0 (I)
IV (II)
none PR Dead (GVHD), 7 mo
# 17 F/20 NS-IV PR MMRD 5/10 Flu-CTX-TBI CTX/CsA/
MMF
79 1 0 PD Dead (PD), 22 d
# 18 M/31 NS-II PD MMRD 5/10 Thio-Flu-
CTX-TBI
CTX/FK506/
MMF
335 2 0 SD Dead (PD), 12 mo
Benda indicates bendamustine; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; M, male; MC, mixed cellularity; PR, partial response; Treo-Flu-ATG, treosulfan 42 g/m2, ﬂudarabine 150mg/m2,
antithymocyte globulin Fresenius (ATG-Fresenius Neovii Biotech, Munich, Germany) 30 mg/kg, rituximab 500 mg; Rapa/MMF, rapamycine, mycophenolate mofetil; NS, nodular sclerosis; SD, stable disease; F, female; Treo-Flu-
ATG-TBI, treosulfan 42 g/m2, ﬂudarabine 90 mg/m2, antithymocyte globulin Fresenius (ATG-Fresenius Neovii Biotech) 30 mg/kg, total body irradiation 4 Gy; Thio-Flu-CTX, thiotepa 12 mg/kg, ﬂudarabine 60 mg/m2, cyclo-
phosphamide 60mg/kg; CsA/MTX, cyclosporin A andmethotrexate; Thio-Mel-CTX, thiotepa 10mg/kg, melphalan 60mg/m2, cyclophosphamide 100mg/kg; Flu-CTX, ﬂudarabine 60mg/m2 and cyclophosphamide 60mg/kg; Flu-
CTX-TBI, ﬂudarabine 150 mg/m2 and cyclophosphamide 30 mg/kg and total body irradiation 2 Gy; CTX/FK506/MMF, cyclophosphamide 50 mg/kg daysþ3 andþ4 and FK506, mycophenolate mofetil; Thio-Flu-CTX-TBI, thiotepa
12 mg/kg and ﬂudarabine 120 mg/m2 and cyclophosphamide 30 mg/kg and total body irradiation 2 Gy.
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Figure 1. Median OS (solid line) and PFS (broken line) of 18 patients treated
with bendamustine þ/ DLI for HL relapsed after allografting.
E. Sala et al. / Biol Blood Marrow Transplant 20 (2014) 1435e14541446Median number of treatment lines before allo-SCT was 4.5
(range, 3 to 13), always including autologous hematopoietic
stem cell transplantation. Eight patients had chemo-
refractory disease. Four patients (patient no. 2, 14, 15, and 18)
had already received bendamustine before allo-SCT. Median
time to progression after allo-SCT was 7 months (range, 1 to
21). Fourteen patients (78%) had bendamustine as ﬁrst-line
salvage therapy after allo-SCT, whereas 4 had already failed
other salvage approach with second allo-SCT, ifosfamide/
vinblastine, radiotherapy, vinorelbine/gemcitabine and DLI
(patient no. 11), chlorambucil/vinblastine/procarbazine/
prednisolone (ChlVPP), bleomycine/methotrexate and DLI
(patient no. 15), or radiotherapy and DLI (patients no. 12 and
18). A total of 71 cycles of bendamustine were administered
on an outpatient basis with a median of 4 cycles per patient
(range, 1 to 9). According to eligibility criteria speciﬁed
above, only 9 of 18 patients (50%) received DLI. A total of 16
lymphocytes infusions were given, with a median of 2 DLI
among eligible patients (range, 1 to 3). A total of 54 adverse
events (AEs) occurred after bendamustine administration
(44 hematological AEs and 10 nonhematological AEs). Neu-
tropenia grade III to IV developed in 7 patients (39%),
thrombocytopenia grade III to IV in 5 patients (28%), and
grade III anemia in 2 patients (11%). The most common
nonhematologic toxicities were fatigue and nausea (pri-
marily grade I). Four patients experienced serious AE,
possibly related to treatment: febrile neutropenia (n ¼ 1),
idiopathic pneumonia (n ¼ 2), and cytomegalovirus reac-
tivation (n ¼ 3). Six patients had either delay in cycle timing
or dose reduction because of hematological toxicity or
concomitant infections. Among 9 patients undergoing DLI, 3
developed acute grade IV GVHD whereas 3 patients devel-
oped chronic GVHD (2 moderate and 1 severe). Grade IV
acute GVHD was observed in 3 of 4 recipients of hap-
loidentical DLI (patient no. 2 after 1  106 CD3þ T cells/kg,
patient no. 8 after 1  106 CD3þ T cells/kg and 5  106 CD3þ
Tcells/kg, and patient no.16 after .5106 CD3þ Tcells/kg and
1  106 CD3þ T cells/kg). In total, 4 patients required hospi-
talization: 1 for supportive therapy of tumor lysis syndrome
after bendamustine (patient no. 7) and 3 for acute GVHD.
The ORR was 55% with 3 cases of CR and 7 of partial
response, with a median duration of response of 9 months
(range, 1 to 26). Median OS and PFS of the entire cohort
(n ¼ 18) were 11 months (range, 1 to 52) and 6 months
(range, 1 to 28) respectively (Figure 1). One-year OS of re-
sponders (complete or partial, n ¼ 10) was 70% (95% conﬁ-
dence interval [CI], 42% to 98%), and 16% (95% CI, 0 to 44%) for
nonresponders (n¼ 8). Cox regression mortality hazard ratio
of nonresponders versus responders is 5.94 (95% CI, 1.36 to
25.98), P ¼ .02.
DISCUSSION
Several studies have described the use of bendamustine
in heavily pretreated HL patients including patients after
autografts [7-10]. A phase II study of 36 rel/ref HL patients
treated with bendamustine showed 53% ORR, with 33% CR
and a median PFS of 5.2 months [10]. A French study of 28
patients treated with bendamustine for rel/ref HL after
autografting showed very similar results, with ORR 50%, 29%
CR, and 5.7 months PFS [9]. An Italian study described 41
patients, showing 78% ORR, 29% CR, and 11 months PFS [8].
Recently, a multicenter Italian analysis showed the results ofa cohort of 61 rel/ref HL patients rescued with bend-
amustined22 of 61 were in PD after an allograft. The re-
ported ORR was 57%, 25% CR, and 10 months PFS [7]. In
summary, bendamustine is safe and maintains anti-
lymphoma efﬁcacy, also in rel/ref HL, but it works transiently.
Therefore, we hypothesized that bendamustine could pro-
mote tumor debulking and induction of tumor immune-
exposition in preparation for a consolidation strategy with
DLI. Recently, a similar approach has been successfully re-
ported using brentuximab vedotin that selectively induces
immunogenic cell death of lymphoma followed by DLI to
potentiate the graft-versus-lymphoma effect [16].
In our experience, a cohort of 18 HLwho patients relapsed
after an allograft treated with bendamustine and DLI showed
an antilymphoma effect with a favorable toxicity proﬁle. We
observed an ORR of 55% with a 6-month median PFS. One-
year OS of responders was 70% versus 16% for non-
responders. However, it is difﬁcult to ascertain whether the
combination of bendamustine and DLI provided an advan-
tage over single-agent bendamustine. Only prospective
controlled studies will indicate the separate roles of bend-
amustine and DLI in disease control.
In our experience, toxicities in such an advanced clinical
setting were manageable and the rate of hospitalization and
treatment-related mortality was low. Therefore, these data
indicate that the bendamustine-DLI strategy is feasible with
an acceptable safety proﬁle.
The intention of the bendamustine and DLI strategy was
to achieve chemotherapy-induced tumor debulking followed
by the graft-versus-lymphoma effect induced by donor
lymphocytes. Based on the assumption that patients already
experiencing GVHD have exploited the graft-versus-tumor
potential of the SCT immunotherapy [6], DLI was offered
only to patients without previous severe GVHD or without
active GVHD at relapse. According to this GVHD/graft-versus-
lymphoma inducing policy, only one half of patients received
DLI after bendamustine administration. The incidence of
post-DLI GVHD was high and almost inevitable when a
E. Sala et al. / Biol Blood Marrow Transplant 20 (2014) 1435e1454 1447graft-versus-tumor effect was seen. We observed GVHD in 6
of 9 patients receiving DLI, always when given from an
alternative donor (5 from a haplo donor and 1 from a MUD),
whereas no GVHD occurred in 3 patients receiving DLI from a
matched sibling donor. Nevertheless, PD (and not GVHD)was
the main cause of mortality after bendamustine and DLI.
The major limitation of the study is its retrospective
design covering an 8-year period, patient selection, as well as
the confounding factor of variability of treatment schedules.
Given the frail nature of HL in PD after allografting and based
on the incidence of bendamustine-related hematological
toxicity here reported, a dose of bendamustine of 90 mg/m2
should probably be probably pursued at ﬁrst. The DLI dose
should be tailored according to the donor source. Based on
the high incidence of acute GVHD here reported among re-
cipients of haploidentical allo-SCT, a lower starting dose of
1  105 T cells/kg should be considered as a more cautious
option in the haploidentical DLI setting.
In conclusion, these practice-based results showing a
good feasibility proﬁle and an interesting rate of response in
HL relapsing after an allograft suggest that prospective
studies in this setting should be pursued.ACKNOWLEDGMENTS
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